natgillin/translations-raw huggingface dataset:
By extrapolation from erythromycin A and josamycin, concomitant medication of Ketek and alkaloid derivatives could lead to severe vasoconstriction (“ergotism”) with possibly necrosis of the extremities.
Po ekstrapolaciji z eritromicina A in josamicina bi lahko sočasno zdravljenje z zdravilom Ketek in alkaloidnimi derivati povzročilo hudo vazokonstrikcijo ("ergotizem") z možno nekrozo okončin.
By finding the right treatment plan for you, you may be able to slow down this disease process, which may help reduce long-term joint damage, as well as pain and fatigue and improve your overall quality of life.
S pravilnim zdravljenjem se bolezenski proces lahko upočasni, preprečijo dolgoročne poškodbe sklepov, olajša bolečina in utrujenost ter izboljša splošna kakovost življenja.
By increasing levels of dopamine in the parts of the brain that control movement and co-ordination, Azilect improves the signs and symptoms of Parkinson’s disease, such as stiffness and slowness of movement.
Zdravilo Azilect s povečevanjem ravni dopamina v delih možganov, ki nadzorujejo gibe in koordinacijo, lajša znake in simptome Parkinsonove bolezni, kot sta okornost in počasnost gibov.
By increasing levels of dopamine in the parts of the brain that control movement and coordination, Rasagiline Mylan reduces the symptoms of Parkinson’s disease, such as stiffness and slowness of movement.
S povečevanjem ravni dopamina v delih možganov, ki nadzorujejo gibe in koordinacijo, zdravilo Razagilin Mylan lajša simptome Parkinsonove bolezni, kot sta okornost in počasnost gibov.
By increasing levels of dopamine in the parts of the brain that control movement and coordination, Rasagiline ratiopharm improves the signs and symptoms of Parkinson’s disease, such as stiffness and slowness of movement.
S povečevanjem ravni dopamina v delih možganov, ki nadzorujejo gibe in koordinacijo, zdravilo Razagilin ratiopharm lajša znake in simptome Parkinsonove bolezni, kot sta okornost in počasnost gibov.
By increasing levels of incretin hormones in the blood, saxagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high.
Saksagliptin z zviševanjem koncentracije inkretinskih hormonov v krvi spodbuja trebušno slinavko, da tvori več insulina, kadar je raven glukoze v krvi visoka.
By increasing the amount of eumelanin, SCENESSE can help to delay the onset of pain due to skin photosensitivity (sensitive to sunlight).
S povečanjem količine evmelanina lahko zdravilo SCENESSE pomaga upočasniti pojav bolečine zaradi občutljivosti kože za sončno svetlobo.
By independent review, the median progression free survival (PFS) was 3.7 months for eribulin compared to 2.2 months for the TPC arm (HR 0.865, 95% CI: 0.714, 1.048, p=0.137).
Pri neodvisnem pregledu je bilo mediano preživetje brez napredovanja bolezni (PFS – progression free survival) v kraku z eribulinom 3,7 meseca, v kraku s TPC pa 2,2 meseca (HR 0,865, 95-% CI (interval zaupanja): 0,714, 1,048, p=0,137).
By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.
Alirokumab zavre vezavo PCSK9 na LDLR, s tem poveča število LDLR, ki so na voljo za odstranjevanje LDL, in tako zniža koncentracijo LDL-H.
By inhibiting the DPP--4 enzyme, sitagliptin increases the levels of two known active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Z zaviranjem encima DPP-4 sitagliptin zviša raven dveh znanih inkretinskih hormonov, glukagonu podobnega peptida-1 (GLP-1 - glucagon- like peptide-1) in od glukoze odvisnega insulinotropnega polipeptida (GIP - glucose-dependent insulinotropic polypeptide).
By inhibiting the DPP-4 enzyme, sitagliptin increases the levels of two known active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Z zaviranjem encima DPP-4 sitagliptin zviša raven dveh znanih inkretinskih hormonov, glukagonu podobnega peptida-1 (GLP-1 - glucagon- like peptide-1) in od glukoze odvisnega insulinotropnega polipeptida (GIP - glucose-dependent insulinotropic polypeptide).
By inhibiting the enzyme renin, aliskiren inhibits the RAS at the point of activation, blocking the conversion of angiotensinogen to angiotensin I and decreasing levels of angiotensin I and angiotensin
Z zaviranjem encima renina aliskiren zavre delovanje sistema renin-angiotenzin na točki aktivacije, saj zavre pretvorbo angiotenzinogena v angiotenzin I in tako zniža ravni angiotenzina I in angiotenzina II.
By inhibiting tubulin polymerization, both DM1 and trastuzumab emtansine cause cells to arrest in the G2/M phase of the cell cycle, ultimately leading to apoptotic cell death.
Z zavrtjem polimerizacije tubulina DM1 in trastuzumab emtanzin ustavita celice v fazi celičnega ciklusa G2/M in navsezadnje povzročita apoptotično smrt celic.
By intent to treat analysis 65 % of patients had HIV RNA < 400 copies/mL and 50 % had viral load < 50 copies/mL; by on-treatment analysis 96 % of patients had HIV RNA
Pri analizi populacije, ki so jo nameravali zdraviti, je imelo 65 % bolnikov HIV RNA < 400 kopij/ml, 50 % pa virusno breme < 50 kopij/ml; pri analizi zdravljene populacije je imelo 96 % bolnikov HIV
by Kaletra.
fenobarbitalom se koncentracija
By looking though the inspection window, the solution should be clear to slightly opalescent, colourless or pale yellow and may contain small translucent or white particles of protein.
Pri pogledu skozi okence za pregledovanje mora biti raztopina bistra do rahlo opalescentna, brezbarvna ali bledo rumena ter lahko vsebuje majhne prosojne ali bele delce beljakovine.
By lowering the heart rate, Corlentor reduces the stress on the heart, thereby slowing the progression of heart failure and improving symptoms.
Zdravilo Corlentor z zniževanjem srčnega utripa zmanjša obremenitev za srce ter upočasni napredovanje srčnega popuščanja in ublaži simptome.
By lowering the heart rate, Procoralan reduces the stress on the heart, thereby slowing the progression of heart failure and improving symptoms.
Zdravilo Procoralan z zniževanjem srčnega utripa zmanjša obremenitev za srce ter upočasni napredovanje srčnega popuščanja in ublaži simptome.
By lowering the pressure, Izba reduces the risk of damage.
Zdravilo Izba z zniževanjem tlaka zmanjša nevarnost poškodb.
By mimicking the action of thrombopoietin, romiplostim stimulates the production of platelets, increasing blood platelet counts.
S posnemanjem delovanja trombopoetina ta spodbuja nastajanje trombocitov in tako poveča njihovo število v krvi.
by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation in muscle; by delaying intestinal glucose absorption.
z zmernim povečanjem občutljivosti za insulin, s čimer izboljša periferni privzem glukoze in porabo v mišicah, z upočasnitvijo absorpcije glukoze iz črevesa.
by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation; by delaying intestinal glucose absorption.
zmerno poveča občutljivost za insulin in tako izboljša periferni privzem in uporabo glukoze. upočasni absorpcijo glukoze iz črevesa.
by mouth.
peroralno (skozi usta),
by pain is resolved or healing is
oziroma ne dosežemo celjenja.
by pain is resolved or healing is
ustavi oziroma dokler ne dosežemo celjenja.
by pooling from the vials either into larger syringe (a) or an infusion bag (b) as directed by your healthcare professional, depending upon the variable rate infusion pump to be used; or directly from the IG vial (c).
z združevanjem vial v večjo brizgo (a) ali v infuzijsko vrečo (b) po navodilih zdravstvenega delavca, odvisno od uporabljene infuzijske črpalke s spremenljivo hitrostjo, bodisi neposredno iz viale IG (c).
By preventing interleukin-6 attaching to its receptors, tocilizumab reduces the inflammation and other symptoms of these diseases.
Tocilizumab s preprečevanjem vezanja interlevkina-6 na ustrezne receptorje zmanjša vnetje in druge simptome teh bolezni.
By preventing the breakdown of bones, Zoledronic Acid Accord also helps to reduce the amount of calcium released into the blood.
Zdravilo Zoledronic Acid Accord s preprečevanjem razgradnje kosti pripomore tudi k znižanju ravni kalcija, ki se sprošča v kri.
By Q3 2024
3. kvartal 2024
By reconstitution of the immunogen in the oil emulsion the stimulation of immunity after injection is prolonged.
Po predhodni rekonstituciji zdravilne učinkovine v oljni emulziji, se po injiciranju prolongira stimulacija imunosti.
By reducing the flow of potassium through the channels, Multaq prevents the fibrillation from happening and lowers the heart rate.
Zdravilo Multaq z zmanjšanjem pretoka kalija skozi kanale prepreči nastop fibrilacije in zniža srčni utrip.
By reducing the production of prostaglandins in the eye, Yellox can reduce the inflammation caused by eye surgery.
Ob jemanju zdravila Yellox se zmanjša tvorjenje prostaglandinov v očesu, kar ublaži vnetje, ki ga povzroči operacija očesa.
By reducing the production of prostaglandins, EQUIOXX helps reduce the symptoms of inflammation, including pain.
Zdravilo EQUIOXX z zmanjšanjem nastajanja prostaglandinov pomaga zmanjšati simptome vnetja, vključno z bolečino.
by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis
z zaviranjem glukoneogeneze in glikogenolize zmanjšuje nastajanje glukoze v jetrih;
by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis
zmanjšuje nastajanje glukoze v jetrih, tako da inhibira glukoneogenezo in glikogenolizo;
by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis
zmanjšuje nastajanje glukoze v jetrih, tako da zavira glukoneogenezo in glikogenolizo,
by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis in muscle;
z zavrtjem glukoneogeneze in glikogenolize v mišicah zmanjšuje nastajanje glukoze v jetrih.
by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis.
z zaviranjem glukoneogeneze in glikogenolize zmanjšuje nastajanje glukoze v jetrih.
by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis;
z zmanjšanjem nastajanja glukoze v jetrih z zavrtjem glukoneogeneze in glikogenolize,
by reduction of hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis;
zmanjšuje tvorbo glukoze v jetrih, tako da zavira glukoneogenezo in glikogenolizo;
By replacement therapy the plasma levels of factor IX are increased, thereby enabling a temporary correction of the factor IX deficiency and correction of the bleeding tendencies.
Z nadomestnim zdravljenjem povišamo plazemske ravni faktorja IX in tako omogočimo začasno poboljšanje pomanjkanja faktorja IX in popravo tendence h krvavitvam.
By replacing the BH4 that the body cannot produce, Kuvan reduces the harmful excess of phenylalanine in the blood and increases the dietary tolerance to phenylalanine.
Zdravilo Kuvan nadomesti BH4, ki ga telo ne more tvoriti in tako zmanjša škodljive učinke fenilalanina v krvi in poveča sposobnost prenašanja hrane s fenilalaninom.
By replacing the missing hormones, Pergoveris allows women with FSH and LH deficiency to develop a follicle, which will release an egg after an injection of the hormone human chorionic gonadotrophin (hCG).
Zdravilo Pergoveris z nadomeščanjem manjkajočih hormonov omogoči, da se pri ženskah s pomanjkanjem FSH in LH razvije folikel, iz katerega se bo po injekciji hormona humani horionski gonadotropin (hCG) sprostilo jajčece.
By replacing the missing hormones, Pergoveris allows women with low levels of FSH and LH to develop a follicle.
Z nadomestitvijo manjkajočih hormonov zdravilo Pergoveris ženski z nizkimi ravnmi FSH in LH omogoča razvoj folikla.
by rifampicin.
brez prilagajanja odmerka.
by September
do septembra
by slow injection into a vein (intravenous infusion) over about 1 hour.
počasno injekcijo v veno (intravenska infuzija) infuzija bo trajala približno 1 uro
by stimulating the immune system to attack the cancer cells by stopping the formation of blood vessels supplying the cancer cells.
podbuja imunski sistem, da napada rakave celice, ustavi nastajanje krvnih žil, ki preskrbujejo rakave celice.
by stopping blood vessels growing in the cancer by stimulating part of the immune system to attack the cancer cells.
ustavi rast krvnih žil v raku, spodbuja del imunskega sistema, da napada rakave celice.
by stopping blood vessels growing in the cancer by stimulating part of the immune system to attack the cancer cells.
ustavlja rast krvnih žil v rakavem delu spodbuja dele imunskega sistema k napadanju rakavih celic
By stopping protease from working, Telzir stops HIV multiplying and infecting more CD4 cells
Zdravilo Telzir prekine delovanje proteaze in s tem ustavi razmnoževanje virusa HIV ter prepreči okužbo dodatnih celic CD4.
By stopping reverse transcriptase from working, Nevirapine Teva helps control HIV-1 infection.
S tem, ko ustavi delovanje reverzne transkriptaze, zdravilo Nevirapine Teva pomaga nadzorovati okužbo s HIV- 1.
by stopping the cancer cells developing
ustavi razvoj rakavih celic,
by stopping the cancer cells developing
ustavlja razvoj rakavih celic
by stopping the myeloma cells developing
ustavi razvoj plazmocitomskih celic,
By study design, patients in the long-term extension may have switched bewtween the 50 mg and 100 mg Simponi doses at the discretion of the study physician.
V skladu z načrtom študije, so bolniki v dolgotrajnem podaljšanju po presoji zdravnika lahko zamenjali med 50-mg in 100-mg odmerkom zdravila Simponi.
By taking them both together, you might make ellaOne less effective.
Sočasna uporaba lahko povzroči, da bo zdravilo ellaOne manj učinkovito.
By targeting this enzyme and blocking its effects, idelalisib causes death of the cancer cells, thereby delaying or stopping the progression of the cancer.
Idelalizib s ciljnim delovanjem na ta encim in zaviranjem njegovega delovanja povzroča smrt rakavih celic in tako odloži ali ustavi napredovanje raka.
by the
Ni raziskan.
By the 7th day, the median aripiprazole concentrations further decline to concentrations following an IM depot dose with no dose dumping.
Do 7. dne naj bi mediana koncentracij aripiprazola še naprej upadala do koncentracij po i.m. depo odmerku brez sprostitve celotnega odmerka hkrati.
By the end of Day 6 you will have reached this recommended dose.
Ta priporočeni odmerek boste dosegli ob koncu 6. dne.
by therapeutic area
zdravila po
By this mechanism, efalizumab inhibits the binding of LFA-1 to ICAM-1, which interferes with T lymphocytes adhesion to other cell types.
S tem mehanizmom efalizumab inhibira vezavo LFA-1 na ICAM-1 (medcelična adhezijska molekula- 1), kar moti adhezijo limfocitov T na druge tipe celic.
by tipranavir/r, lansoprazole and
2C19, je lansoprazolovo in
by tipranavir/r.
inducira.
By two weeks post administration the maximum size had decreased to 8 x 4 cm, showing a gradual resolution of the local reactions.
Do drugega tedna po dajanju se je največja velikost zmanjšala na 8 x 4 cm, kar kaže na postopno izginevanje lokalne reakcije.
By virtue of binding to this site, pleuromutilins inhibit peptidyl transfer, partially block P-site interactions, and prevent normal formation of active 50S ribosomal subunits.
Z vezavo na to mesto pleuromutilini zavirajo prenos peptidila, deloma ovirajo interakcije P-mesta in preprečijo normalno formiranje aktivnih 50S ribosomskih podenot.
By virtue of its α2-adrenergic activity, dexmedetomidine causes a decrease in heart rate and body temperature.
Deksmedetomidin zaradi α2-adrenergičnega delovanja povzroča znižanje srčnega utripa in telesne temperature.
By week 12 (n= 215)
Do 12. tedna (n= 215)
By Week 12 (n=215)
Do 12. tedna (n= 215)
By Week 12*** (n= 915)
Do 12. tedna*** (n=915)
By week 12*** (n=915)
Do 12. tedna*** (n=915)
By week 26, twenty weeks after the last induction dose, 30% of patients in the 5 mg/kg group and 13.8% of patients in the 3 mg/kg group were PASI 75 responders.
Do 26. tedna, t.j. dvajset tednov po zadnjem uvodnem odmerku, je 30 % bolnikov iz skupine, ki je prejemala 5 mg/kg, in 13,8 % bolnikov iz skupine, ki je prejemala 3 mg/kg, imelo odziv PASI 75.
By Week 4*** (n= 950)
Do 4. tedna*** (n=950)
By week 4*** (n=950)
Do 4. tedna*** (n=950)
Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen exenatide
Bydureon 2 mg prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje v napolnjenem injekcijskem peresniku. eksenatid
Bydureon is a diabetes medicine that contains the active substance exenatide.
Bydureon je zdravilo za zdravljenje sladkorne bolezni, ki vsebuje zdravilno učinkovino eksenatid.
Bydureon is given as one injection under the skin once a week on the same day each week in the abdomen (belly), thigh or back of the upper arm.
Zdravilo Bydureon se daje kot ena injekcija pod kožo enkrat tedensko, na isti dan v tednu, v trebuh, stegno ali zadnji del nadlakti.
Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with
Zdravilo Bydureon je indicirano za zdravljenje diabetesa mellitusa tipa 2 v kombinaciji z:
Bydureon is used to treat type 2 diabetes.
Zdravilo Bydureon se uporablja za zdravljenje sladkorne bolezni tipa 2.
Bydureon was investigated in four main studies lasting six months or more involving a total of 1,525 patients with type 2 diabetes.
Zdravilo Bydureon je bilo raziskano v štirih glavnih študijah, ki so trajale šest mesecev ali več in pri katerih je sodelovalo skupaj 1 525 bolnikov s sladkorno boleznijo tipa 2.
BYETTA
BYETTA BYETTA
Byetta 10 mcg injection exenatide Subcutaneous use
Byetta 10 µg injekcija eksenatid za subkutano uporabo
Byetta 10 micrograms solution for injection in pre-filled pen (exenatide)
Byetta 10 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku (eksenatid)
Byetta 5 mcg injection exenatide Subcutaneous use
Byetta 5 µg injekcija eksenatid za subkutano uporabo
Byetta 5 micrograms solution for injection in pre-filled pen (exenatide)
Byetta 5 mikrogramov raztopina za injiciranje v napolnjenjem injekcijskem peresniku (eksenatid)
Byetta 5 micrograms solution for injection in pre-filled pen Byetta 10 micrograms solution for injection in pre-filled pen
Byetta 5 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Byetta 10 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku
Byetta 5 micrograms solution for injection in pre-filled pen Byetta 10 micrograms solution for injection in pre-filled pen exenatide
Byetta 5 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku Byetta 10 mikrogramov raztopina za injiciranje v napolnjenem injekcijskem peresniku eksenatid
Byetta contains sodium
Zdravilo Byetta vsebuje natrij
Byetta is for use by one person only.
Zdravilo Byetta je za uporabo le za eno osebo.
Byetta is indicated for treatment of type 2 diabetes mellitus in combination with:
Zdravilo Byetta je indicirano za zdravljenje diabetesa mellitusa tipa 2 v kombinaciji z:
Byetta is injected twice a day, the pen contains enough medicine for 30 days.
Zdravilo Byetta se injicira dvakrat na dan, tako da injekcijski peresnik vsebuje količino zdravila za 30 dni.
Byetta Liquid
Zdravilo Byetta
Byetta should come from needle tip.
Zdravilo Byetta bi moralo priteči iz konice igle.
Byk-Gulden-Straße 2 D-78467 Konstanz Germany
Byk-Gulden- Straße 2 D-78467 Konstanz Nemčija
Byk-Gulden-Straße 2 D-78467 Konstanz Germany
Byk-Gulden-Straße 2 D-78467 Konstanz Nemčija
Bz n=202a
TTP
Bzmb n=187
n=145
Bzmb n=193
p-vrednosta
Bzmb=Bortezomib SUN; Dx=dexamethasone; T=thalidomide a Thalidomide dose is increased to 100 mg from week 3 of cycle 1 only if 50 mg is tolerated and to 200 mg from cycle 2 onwards if 100 mg is tolerated. b Up to 6 cycles may be given to patients who achieve at least a partial response after 4 cycles
Bzmb= Bortezomib SUN; Dx=deksametazon; T=talidomid a V 3. tednu 1. kroga se lahko odmerek talidomida poveča na 100 mg samo, če bolnik dobro prenaša odmerek 50 mg in na 200 mg v 2. krogu, če bolnik dobro prenaša odmerek 100 mg. b Bolniki, ki dosežejo vsaj delni odziv po 4 krogih, lahko prejmejo do 6 krogov zdravljenja.
Bzmb=Bortezomib SUN; M=melphalan, P=prednisone
Bzmb= Bortezomib SUN; M=melfalan, P=prednizon
BzmbR-CAP=bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy
BzmbR-CAP=bortezomib, rituksimab, ciklofosfamid, doksorubicin in prednizon; R-CHOP= rituksimab ciklofosfamid, doksorubicin, vinkristin in prednizon; PN=periferna nevropatija
BzR-CAP=Bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy
BzR-CAP=bortezomib, rituksimab, ciklofosfamid, doksorubicin in prednizon; R-CHOP= rituksimab, ciklofosfamid, doksorubicin, vinkristin in prednizon; PN=periferna nevropatija
C (n=1), D (n=66), and the circulating recombinant forms (CRFs) AD (n=9), CD (n=1), and a complex inter-subtype recombinant_cpx (n=1), a second study of 18 isolates including subtype G (n=14) and CRF_AG (n=4) from Nigeria, and a third study of six isolates (n=4 CRF_AG, n=1 A and n=1 undetermined) from Abidjan (Côte d'Ivoire).
Druga študija je zajela 18 izolatov, vključno s podtipom G (n = 14) in CRF_AG (n = 4) iz Nigerije, tretja pa šest izolatov (n = 4 CRF_AG, n = 1 A in n = 1 nedoločen) iz Abidjana (Slonokoščena obala).
c 48 weeks of double-blind adefovir dipivoxil followed by 48 weeks open-label tenofovir disoproxil fumarate. d The population used for analysis of ALT normalisation included only patients with ALT above ULN at baseline.
c 48-tedensko dvojno slepo zdravljenje z dipivoksiladefoviratom, ki mu sledi 48-tedensko odprto zdravljenje z dizoproksiltenofovirijevim fumaratom. d V populaciji, ki so jo uporabili za analizo normalizacije ALT, so bili samo bolniki z ravnjo ALT nad ZMN v izhodiščni točki.
C 60 mg/m2 i.v., days 22-25, 29-32
Ara-C 60 mg/m2 i.v., 22.-25., 29.-32. dan
c > 48 hours of diarrhoea and/or > 7 days of rash d If patient cannot tolerate 20 mg/day, permanent discontinuation of GIOTRIF should be considered
c > 48 ur driske in/ali > 7 dni izpuščaja d Če bolnik ne prenaša odmerka po 20 mg na dan, je treba presoditi o ukinitvi zdravila GIOTRIF.
c Adverse reaction observed with Rasilez HCT
c neželeni učinki, ki so jih opažali pri uporabi zdravila Rasilez HCT
C Adverse reaction originates from saxagliptin or dapagliflozin post-marketing surveillance data.
C Neželeni učinki izvirajo iz podatkov o spremljanju med obdobjem trženja saksagliptina oz. dapagliflozina.
c Age at first dose: 1 to 6 months
c Starost ob prvem odmerku: 1 do 6 mesecev
c Based on Kaplan-Meier product limit estimates. d Based on Log rank test stratified with IPI risk and stage of disease. e Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and stage of disease as stratification factors.
c Ocena po metodi Kaplan-Meier. d Na osnovi Log rank testa, stratificiranega z IPI tveganjem in stopnjo bolezni. e Uporabljena je Mantel-Haenszelova ocena razmerja verjetnosti za stratificirane preglednice, skupaj s stratifikacijskima dejavnikoma IPI tveganjem in stopnjo bolezni.
c Based on Kaplan-Meier product limit estimates. d Based on Log rank test stratified with IPI risk and stage of disease. e Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and stage of disease as stratification factors.
c Ocena po metodi Kaplan-Meier. d Na podlagi log-rank testa, stratificiranega z IPI-tveganjem in stadijem bolezni. e Uporabljena je Mantel-Haenszelova ocena razmerja obetov za stratificirane preglednice, skupaj s stratifikacijskima dejavnikoma IPI-tveganjem in stadijem bolezni.
c CANCIDAS is formulated to provide the full labelled vial dose (50 mg) when 10 ml is withdrawn from the vial.
Zdravilo CANCIDAS je pripravljeno tako, da zagotavlja polni, na viali označeni odmerek (50 mg), če iz viale potegnete 10 ml.